UK Markets open in 2 hrs 31 mins

Celsion Corporation (CLSN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.8700-0.0300 (-3.33%)
At close: 4:00PM EST

Celsion Corporation

997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States
609 896 9100

Full-time employees29

Key executives

NameTitlePayExercisedYear born
Mr. Michael H. TardugnoExec. Chairman, Pres & CEO786.91kN/A1951
Mr. Jeffrey W. Church CPA, CPACFO, Exec. VP & Corp. Sec.455.92kN/A1957
Dr. Khursheed AnwerExec. VP & Chief Scientific Officer409.32kN/A1960
Dr. Nicholas BorysExec. VP & Chief Medical Officer505.98kN/A1959
Mr. Timothy J. TumminelloChief Accounting Officer & ControllerN/AN/A1958
Ms. Marianne M. LambertsonVP of Communications & Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Corporate governance

Celsion Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.